These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 12505751

  • 1. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J, Yamagishi Si, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [Abstract] [Full Text] [Related]

  • 2. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
    Hirata K, Kubo K.
    Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
    [Abstract] [Full Text] [Related]

  • 3. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA, Elewa A, Arafa LF.
    Eur J Ophthalmol; 2011 Dec; 21(1):48-54. PubMed ID: 20544678
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
    Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL.
    Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
    Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G.
    Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
    Aso Y, Inukai T, Tayama K, Takemura Y.
    Acta Diabetol; 2000 Sep; 37(2):87-92. PubMed ID: 11194933
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
    Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG.
    Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
    [Abstract] [Full Text] [Related]

  • 16. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
    Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, DCCT Skin Collagen Ancillary Study Group.
    Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Nov; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

  • 19. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
    Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, Monnier VM, TINSAL-T2D Research Consortium.
    Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
    [Abstract] [Full Text] [Related]

  • 20. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
    O'Grady KL, Khosla S, Farr JN, Bondar OP, Atkinson EJ, Achenbach SJ, Eckhardt BA, Thicke BS, Tweed AJ, Volkman TL, Drake MT, Hines JM, Singh RJ.
    J Appl Lab Med; 2020 May 01; 5(3):558-568. PubMed ID: 32445362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.